FDA label 5f23c2eb-6b09-448b-bad1-b2c377a24fc7
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- SPL set ID
- 1d246801-b840-4692-8d53-72682f78bf63
- SPL ID
- 5f23c2eb-6b09-448b-bad1-b2c377a24fc7
- Version
- 1
- Effective date
- 2012-03-12
- Source export date
- 2026-10-12
- Source partition
- 11
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0011-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-10-12/a497e765d824a2e2aa9e88d5f0eea2aae9dcba363989e5f163395cda5c3c9dd8/drug-label-0011-of-0014.json.zip
- Source manifest SHA-256
- 7e6b178df8f32cac9a78e0f5d09c588344509b04fe41effb1dde9102e2a45be6
- Import run
- 20261013T011858Z
- Imported at
- 2026-10-13 02:48:22
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| spl id | 5f23c2eb-6b09-448b-bad1-b2c377a24fc7 | id | |
| spl set id | 1d246801-b840-4692-8d53-72682f78bf63 | set_id |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS FOR EXTERNAL USE ONLY. KEEP OUT OF REACH OF CHILDREN. Avoid contact with eyes, eyelids, lips and mucous membranes. If inadvertent contact occurs, rinse area thoroughly with water. Contact with colored material, including fabric and hair, may result in discoloration. When using Clinac® BPO 7, avoid unnecessary sun exposure and use a sunscreen. In case of accidental ingestion, seek professional assistance or contact a poison control center immediately.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS Allergic contact dermatitis and dryness have been reported with topical benzoyl peroxide therapy. If excessive scaling, erythema or edema occurs, the use of Clinac® BPO 7 should be discontinued and appropriate therapy instituted. To hasten resolution of adverse effects, cool compresses may be used. After reaction clears, a reduced dosage schedule may often be resumed if the reaction is judged not to be due to allergenicity.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.